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Introduction: Plasminogen activator inhibitor-1 (PAI-1), a known inhibitor of plasminogen activators, may regulate
smooth muscle cell migration (SMC) through alteration in matrix metalloproteinase (MMP) activity.
Methods: To study the effect of endothelial cell (EC) PAI-1 overexpression on SMC migration, RT-PCR was used to clone
the full length PAI-1 gene, which was ligated into the pCMV/myc/ER expression vector. With electroporation, bovine
aortic ECs were transfected with either the PAI-1 construct or the empty vector as control. EC PAI-1 overexpression was
shown with a specific PAI-1 activity assay and enzyme-linked immunosorbent assay. The effect of EC PAI-1 overexpres-
sion on SMC migration was measured with a modified Boyden-chamber assay. SMC MMP expression was measured with
zymography.
Results: Selected clones (EC9, EC21) had a three-fold to five-fold increase in PAI-1 activity compared with untransfected
EC and empty vector EC (ECC). Similarly, enzyme-linked immunosorbent assay results showed a 3.5-fold to 5.5-fold
increase in PAI-1 levels in EC9 and EC21 versus ECC. Untransfected EC and ECC had similar effects on SMC migratory
patterns. Migration of SMC exposed to PAI-1 overexpressing EC was inhibited by 35% to 57% compared with ECC. This
inhibitory effect was reversed with addition of exogenous urokinase-type plasminogen activator (uPA). Zymography
showed downregulation of MMP-2 and MMP-9 in SMCs exposed to PAI-1 overexpressing EC.
Conclusion: PAI-1 overexpression with transfected EC inhibits SMC migration. This effect may be mediated through
decreased SMC MMP activity. (J Vasc Surg 2002;36:164-71.)
Intimal hyperplasia is the leading cause of restenosis
and failure of peripheral angioplasty and bypass procedures.
This intimal hyperplastic response seen in human arteries
after vessel wall injury has been well described and is
mediated predominantly with vascular smooth muscle
cells (SMCs).1 During the development of intimal hy-
perplasia, SMCs first migrate to the subintimal space
where they proliferate and produce abundant extracellu-
lar matrix (ECM), which accounts for most of the mature
lesion.2,3
For migration to the intima of the vessel wall, SMCs
must degrade the surrounding matrix. Clowes and
Schwartz4 and other investigators5,6 have shown that the
urokinase-type plasminogen activator (uPA)-plasmin-
matrix metalloproteinase (MMP) axis is involved in the
degradation of this existing ECM. uPA is known to
convert plasminogen to plasmin, which in turn activates
MMPs.7,8 These activated MMPs coordinate the degra-
dation of existing ECM. Plasminogen activator inhibi-
tor-1 (PAI-1), a known inhibitor of uPA, may play a
significant role in regulating this pathway.9 Evidence
for this is provided by Carmeliet et al10-13 with a
PAI-1 knockout mouse model in which PAI-1 deficient
mice had a more severe intimal hyperplastic response
to arterial injury when compared with wild type
controls. One explanation for these findings is that
PAI-1 inhibits uPA-mediated activation of plasmin,
which in turn limits MMP activity.14 This may lead to
less degradation of ECM and a potential decrease in
SMC migration.15
Endothelial cells (ECs) are the major source of PAI-1
in the arterial wall. ECs have been shown to favorably
affect arterial wall remodeling after arterial injury.16 One
possible mechanism with which this occurs is through
inhibition of SMC migration as a result of PAI-1 secre-
tion from the abluminal surface of the EC.17,18 This has
recently been shown by Redmond and coworkers.19
These authors have shown that ECs inhibit SMC migra-
tion in a coculture system through a PAI-1 mechanism.
In this study, we have developed EC clones that overex-
press PAI-1. The purpose of this study was to determine
whether EC overexpression of PAI-1 inhibited SMC
migration. In addition, we examined the role of MMP-9
in this process. Lastly, we examined the spreading, at-
tachment, and proliferation of the PAI-1 overexpressing
EC to determine whether the transfection process al-
tered the proliferation, attachment, or spreading of the
experimental cell lines.
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Construction of plasminogen activator inhibitor-1
plasmid. Total RNA was extracted from bovine EC with
guanidium thiocyanate.20 The isolated RNA was reverse
transcribed into complementary DNA with the manufac-
turer’s random primer protocol (Boehringer-Mannheim,
Inc, Indianapolis, Ind). The 1.2-kilobase PAI-1 comple-
mentary DNA was made double stranded in a polymerase
chain reaction containing primers specifically designed to
amplify the 1.2-kilobase porcine PAI-1 DNA and incorpo-
rate 5 Sal I and 3 Not I restriction enzyme sites. The
primer sequences are 5 primer, 5 GCGTCGA-
CAAGCTTTTTGCCGAAGGC 3, and 3 primer 5
ATATATGCGGCCGCGTCAAGGCTCCATCACTT 3.
PCR conditions were as follows: 95° C, 5 minutes; 58° C,
1 minute; add DNA Taq polymerase; 72° C, 1 minute 15
seconds for 1 cycle followed by 95° C, 1 minute; 58° C, 1
minute; add DNA Taq polymerase; 72° C, 1 minute 15
seconds for 34 cycles.
The restriction enzyme sites on the PCR product were
activated. PAI-1 was ligated into the pCMV/myc/ER
shuttle vector (Invitrogen, Inc, Carlsbad, Calif), enabling
DNA amplification in prokaryotic cells and protein expres-
sion in eukaryotic cells. The vector contains both ampicillin
and G-418 resistance genes for prokaryote and eukaryote
cells, respectively. The ligated construct then was intro-
duced into TOP 10 Escherichia coli cells (Invitrogen, Inc,
Carlsbad, Calif) with electroporation with the BTX 600
Electro Cell Manipulator (Genetronics, Inc, San Diego,
Calif). The transformed cells were selected on Luria broth
agar plates containing 100 g/mL of ampicillan. Individ-
ual colonies were isolated and grown at 37° C for 12 hours
in Luria broth (Quality Biological, Inc, Gaithersburg, Md)
containing 100 g/mL ampicillan. DNA was isolated with
a Qiagen plasmid purification kit (Qiagen, Inc, Valencia,
Calif). Restriction enzyme digestion of plasmidal DNA was
performed to confirm the presence of PAI-1. DNA se-
quencing was performed to verify the fidelity of the PAI-
1/pCMV/myc/ER construct.
Cell culture and transfection. ECs were isolated
from bovine thoracic aorta with collagenase technique and
allowed to grow in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% calf bovine serum (Hy-
Clone Laboratories, Inc, Logan, Utah), penicillin (40
units/mL), streptomycin (40 mg/mL), and 4.8 mmol/L
L-glutamine. EC identity was confirmed after each passage
and after transfection with cobblestone morphology and
also factor VIII-related antigen (cat# A616, DAKO Corp,
Carpinteria, Calif) and lectin Bandeiraea simplicifolia BS-1
staining (cat# L-2140, Sigma, St Louis, Mo).21 SMCs were
isolated from bovine thoracic aorta with the explant tech-
nique. SMC identity was confirmed after each passage with
staining for -actin (Sigma).
Cells were transfected with the PAI-1 construct with
the electroporation technique. Transfected cells were
grown in DMEM containing the antibiotic G-418. Resis-
tant clones were selected and tested for PAI-1 activity. The
pCMV/myc/ER vector without the PAI-1 insert also was
transfected into EC to function as a control (empty vector
EC [ECC]).
Plasminogen activator inhibitor-1 assays. A modi-
fied spectrophotometric assay as described by Verheijen et
al22 was used to measure PAI-1 protein activity in the
conditioned media from ECs. In this assay, plasmin cleaves
Chromozym-PL, resulting in a p-nitroniline molecule that
absorbs at 405 nm. Briefly, conditioned media were col-
lected after 24 hours from confluent ECs (1 106 cells/25
mm2-area circular well) and centrifuged to remove cellular
debris. After this, 40 L of fresh conditioned media were
added to 0.2 units of uPA (American Diagnostica, Inc,
Greenwich, Conn). This was incubated at 25° C for 1 hour,
after which 15 g/mL of Chromozym-PL and 1 unit of
plasminogen (Boehringer Mannheim, Inc) were added.
This was incubated at 37° C for 45 minutes, and PAI-1
activity was quantified with measuring absorbance at 405
nm on an EL-311 Microplate Autoreader (Bio-Tek Instru-
ments, Burlington, Vt).
Quantification of PAI-1 protein also was performed
with the IMUBIND tissue PAI-1 enzyme-linked immu-
nosorbent assay (ELISA) kit as described by the manufac-
turer (American Diagnostica, Inc). Briefly, standards and
samples were incubated in 96-well microtiter wells pre-
coated with anti-human PAI-1 antibody. After washing,
the secondary biotinylated anti-PAI-1 detection antibody
was added along with the enzyme conjugate, streptavidin-
horseradish peroxidase. The amount of streptavidin-horse-
radish peroxidase bound was determined with addition of
perborate/3, 3, 3, 5-tetramethylbenzidine substrate. The
reaction was stopped with sulfuric acid, and the assay was
quantified with measurement of absorbance at 450 nm on
an EL-311 Microplate Reader.
Smooth muscle cell migration studies. A modified
Boyden-chamber assay was used to study the effect of EC
overexpressing PAI-1 on SMC migration.23,24 The assay
was run with both coated and uncoated polycarbonate
8-m porous membranes (Corning Costar Corp, Cam-
bridge, Mass). Coated filters were covered with growth
factor reduced basement membrane gel matrix (Matrigel,
Becton Dickinson, Inc, Franklin Lakes, NJ) at a concentra-
tion of 100 g/mL. The membrane was exposed to the
Matrigel for 1 hour, then washed with Hank’s Balanced
Salt Solution and allowed to dry overnight. ECs were
allowed to grow to confluence in the bottom of a 12-well
plate. After the ECs had conditioned the media for 24
hours, the inserts containing porous membranes were
placed into each well. Bovine aortic SMCs were grown to
confluence in T-75 flasks and made quiescent in serum-free
DMEM, harvested in 0.05% trypsin-ethylenediamine tet-
raacetic acid, and resuspended in serum-free DMEM.
SMCs were seeded on the membrane supports at a concen-
tration of 100,000 cells per well. Migration of the SMC
toward the EC was assayed for 4 hours at 37° C. The
membranes were removed, fixed in 70% ethyl alcohol for 20
minutes, and stained in hematoxylin overnight. The mem-
branes were rinsed in water and then mounted on micro-
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scope slides. Migration was quantified with counting cells
in five high-power fields for each membrane with micros-
copy. All assays were run in triplicate.
Zymography. Gelatin zymography was performed as
previously described with lysate from SMC grown in cocul-
ture with transfected and untransfected EC.25 SMCs were
seeded on a 0.4-m porous polycarbonate membrane and
cocultured with EC for 4 hours. SMCs were removed from
the plate with homogenization buffer (50 mmol/L Tris-
HCL, 10 mmol/L CaCl2, 0.2% tritin X-100, pH 7.5). The
cell membranes were fractured in three freeze/thaw cycles,
after which protein levels were determined with a standard
Bradford assay. Equivalent amounts of total soluble protein
were electrophoresced on a 10% sodium dodecylsulfate-
polyacrylamide gel electrophoresis gel containing 0.1% gel-
atin (Bio-Rad, Inc, Hercules, Calif). After electophoresis,
the gel was washed in 2.5% Triton X-100 to remove the
sodium dodecylsulfate. The gel was developed for 18 hours
at 37° C in a solution containing 50 mmol/L Tris-HCL
(pH 7.9) and 5 mmol/L CaCl2. The solution was re-
moved, and the gel was fixed in 10% acetic acid/40%
methanol and then stained with coomassie blue.
Control zymograms were performed in a similar fash-
ion with samples known to express only MMP-2 (chondro-
sarcoma cell line) or both MMP-2 and MMP-9 (melanoma
cell line).26 Control cell lysates were obtained as a generous
gift from Ulrike Benbow, PhD, Dartmouth Medical
School, Hanover, NH. Gels were photographed, and den-
sitometric analysis of MMP bands was performed with NIH
image 1.62.
Western blot analysis. The SMC lysates isolated and
analyzed with zymography also were used to analyze the
latent form of MMP-9. Samples containing an equivalent
number of SMCs grown in coculture with untransfected
ECs or ECs transfected with pCMV/ER/EC-9 were iso-
lated as described (zymography analysis). An equal amount
of protein from the supernatant of pelleted, lysed cells was
electrophoresed on a 4% to 20% gradient, sodium dodecyl-
sulfate, nonreducing polyacrylamide gel. The proteins were
visualized on a nitrocellulose membrane probed with 1
g/mL of mouse anti-HT1080 latent MMP-9 (Oncogene
Research Products, Boston, Mass). A rabbit antimouse
heavy and light chain antibody (1 g/mL) (Pierce, Rock-
ford, IL) amplified the binding reaction. A 1h incubation
with a horse radish peroxidase-conjugated antibody (don-
key antirabbit immunoglobulin G, Amersham, Arlington
Heights, Ill) diluted 1:10,000 further amplified the bind-
ing reaction. Detection was performed with addition of a
chemiluminescent substrate (Amersham).
Endothelial cell proliferation, attachment and
spreading studies. Transfected and untransfected ECs
were examined to determine whether PAI-1 overexpression
affected their attachment, spreading, or proliferation char-
acteristics with similar methods to those previously de-
scribed.27 For attachment, cells were seeded on glass cover
slips at 5 104 cells per well in 12-well plates. A portion of
the cover slips were left uncoated, and others were pre-
coated with either type I collagen or fibronectin (Sigma) at
a concentration of 10 g/mL in DMEM. Cells were al-
lowed to attach for 20 minutes, and then each well was
washed twice with Hank’s Balanced Salt Solution. Cells
were fixed by adding 4% paraformaldehyde to each well for
1 hour. Cover slips were stained in toluidine blue for 15
minutes, after which time they were rinsed in 70% ethyl
alcohol, allowed to air dry, and mounted on slides. Attach-
ment was quantified with counting total number of cells per
five high-power fields. For spreading, cells were plated at
5  104 on cover slips in 12-well plates and fixed after 1
hour. Cover slips were stained as previously described, and
cell area in m2 was calculated with NIH image 1.62.
Proliferation assays were performed with plating 2.5 105
EC in triplicate into six-well plates. Cells were grown in
DMEM with 10% calf serum. At 24, 48, and 72 hours, cells
were trypsinized and counted with a hemocytometer.
Statistics. All cell culture experiments were performed
in triplicate with EC passages 5 to 10 and SMC passages 1
to 5. Data were tabulated with Microsoft Excel, and statis-
tical analysis was performed with Statview (Abacus Con-
cepts, Inc, Berkeley, Calif) for the Macintosh. Comparisons
were performed with analysis of variance or Student t test or
both, with P less than .05 considered a significant differ-
ence. Error bars represent standard error of the mean.
RESULTS
Plasminogen activator inhibitor-1 construct. We
successfully created a gene construct that overexpressed the
PAI-1 gene. Positive clones were identified on the basis of
size when examined with DNA gel electrophoresis. Cleav-
age of the construct produced two appropriately sized
bands, a 5000-base pair band corresponding to the
Fig 1. Graph shows results of pooled PAI-1 activity assays. PAI-1
activity was determined with spectrophotometric analysis and is
expressed in uPA inhibitory units. Assays run in triplicate, n  5
experiments with cell passages 4 to 8. *P  .05 versus ECC.
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pCMV/myc/ER expression vector and a 1200-base pair
band corresponding to the PAI-1 insert. These results were
confirmed with DNA sequencing of the PAI-1 insert,
which produced an exact match to the known genetic
sequence.28 Our control cell line, ECC, contained only the
empty vector (data not shown).
Plasminogen activator inhibitor-1 activity assay
and enzyme-linked immunosorbent assay. More than
30 clones of transfected EC were tested for PAI-1 activity.
The range of activity varied from no increase over control
EC (ECC) to a five-fold increase in activity. Clone EC9 was
found to have an average three-fold increase over ECC in
PAI-1 activity with activity assay (P  .03) and an average
five-fold increase with ELISA. EC21 had an average two-
fold increase over ECC with activity assay (P .005; Fig 1)
and an average 3.5-fold increase with ELISA (data not
shown). Clones EC9 and EC21 were chosen for further cell
culture experiments.
Smooth muscle cell migration. Bovine aortic SMCs
were exposed to ECs in a modified Boyden-chamber assay
to examine the effect of EC overexpression of PAI-1 on
SMC migration. When nontransfected ECs were compared
with ECCs, no difference was found in migration of SMC
cultured opposite untransfected EC or EC transfected with
the empty vector (ECC; data not shown). Compared with
ECC, SMC migration of cells cultured opposite clone EC9
was decreased by 57%  4% (P  .01) and migration of
SMC grown opposite clone EC21 was decreased by 35%
2% (P  .008; Fig 2, A). A similar trend was seen when
Matrigel-coated membranes were used for the migration
assay (Fig 2 , B). The inhibitory effect on SMC migration
seen with exposure to EC9 could be reversed in a dose-
dependent manner with the addition of increasing amounts
of exogenous uPA to the modified Boyden-chamber media
(Fig 3). At concentrations of uPA from 0.01 to 10 ng/mL,
migration of SMC exposed to clone EC9 was significantly
less than that of SMC exposed to control cells (ECCs). At
higher concentrations of uPA, no difference was seen in
SMC migration between EC9 and ECC.
Metalloproteinase expression. Gelatin zymography
was performed with the cell lysate from SMC exposed to
ECC, EC9, or EC21. A 56% 2% (P .02) and 60% 3%
(P  .03) decrease in MMP-2 expression of SMC exposed
to EC9 and EC21 was found when compared with SMC
exposed to ECC. Similarly, a 40% 4% (P .04) and 44%
 2% (P  .03) decrease in MMP-9 expression in SMC
exposed to EC9 and EC21 was found when compared with
control (Fig 4).
Control zymography was performed with cell lysate
obtained from a chondrosarcoma cell line expressing only
MMP-2 and cell lysate from a melanoma cell line known to
express both MMP-2 and MMP-9. The MMP-9 band is at
Fig 2. SMC migration results from modified Boyden-chamber
assays. Assays were run with uncoated membranes and with Matri-
gel-coated membranes. Migration expressed as number of SMCs
per five high-power fields per membrane. Assays run in triplicate,
n 6 experiments with cell passages 4 to 8. *P .05 versus ECC.
Fig 3. Effect on SMC migration after addition of exogenous uPA
to modified Boyden-chamber assays. Assays run in triplicate, n 6
experiments with cell passages 4 to 8. *P  .05, EC9 versus ECC.
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92 kD, and the bands at 72 and 67 kD correlate with
MMP-2 (Fig 5).
Western analysis also showed decreased latent MMP-9
in SMCs cultured opposite control ECs compared with
SMCs cultured opposite EC9. On the other hand, SMCs
cocultured with EC9 had lower amounts of active MMP-9
compared with controls (Fig 6).
Transfected endothelial cell proliferation and at-
tachment. When ECs were compared with ECCs, no dif-
ference in spreading, attachment, or proliferation was seen
(data not shown). The same morphologic characteristics
for EC9 and EC21 were compared with ECC (Fig 7). We
found no differences in 20-minute attachment between
ECC, EC9, and EC21, even when different attachment
matrices were used. All cell lines had similar spreading
dimensions. No significant differences were seen in prolif-
eration of clones at any time point in the 72-hour assay.
DISCUSSION
Neointimal plaque formation occurs frequently in hu-
man arteries after injury or manipulation during interven-
tional or surgical procedures. This phenomenon has been
studied by other investigators, and various key factors have
been identified that contribute to this process.29 Specifi-
cally, uPA and its known antagonist PAI-1 are thought to
play a role in the development of intimal hyperplasia.30-32
Carmeliet et al12 have shown that PAI-1-deficient mice
displayed accelerated neointimal formation after vascular
Fig 4. Zymogram and densitometric analysis of lysate from SMC
exposed to various EC clones. Clear bands represent MMP degra-
dation of gelatin contained within zymogram substrate. Gelatino-
lytic band at 92 kD corresponds with MMP-9, and 72 kD and 67
kD bands correspond with MMP-2. Densitometric analysis shows
diminished activity of MMP-2 and MMP-9 in SMC cultured
opposite clones EC9 and EC21 versus ECC (n  3 experiments
with cell passages 4 to 8). *P  .05, EC9 versus ECC.
Fig 5. Control zymography shows correlation of MMP-9 and
MMP-2 bands with cell lines known to express specific MMPs.
Lane 1, Lysate from SMC exposed to ECC with bands present for
both MMP-9 and MMP-2; lane 2, lysate from chondrosarcoma
cell line (CON-1) known to express MMP-2 only; lane 3, lysate
from melanoma cell line (CON-2) known to express MMP-9 and
MMP-2; lane 4, low range molecular weight marker (MWM).
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injury compared with mice with normal levels of PAI-1.
Recently, Redmond and coworkers19 have shown that EC
release of PAI-1 inhibits flow induced SMC migration in
coculture. Zempo et al33 found that SMC migration into
the subintima in injured rat carotid arteries is regulated by
MMP-2 and MMP-9 activity. These data were further
validated by the work of Forough et al34,35 and Lijnen et
al36 who found that inhibition of MMPs caused a signifi-
cant decrease in vascular SMC migration both in vitro and
in vivo. In light of these prior findings suggesting that
PAI-1 may play a role in regulation of vascular wall remod-
eling, we examined whether EC overexpression of PAI-1
inhibited SMC migration in vitro. We also sought to deter-
mine whether the mechanism by which this occurs is
through PAI-1 inhibition of SMC MMP activation. In
addition, we examined the morphologic characteristics of
the PAI-1 overexpressing clones to determine whether the
transfection process altered the cell function.
Our control cells, ECCs, which contained the pCMV/
myc/ER vector without the PAI-1 insert, exhibited PAI-1
protein levels similar to untransfected EC. Stimulation of
SMC migration with EC or ECC was equivalent. The EC
cell population that overexpressed PAI-1 inhibited SMC
migration. With the addition of increasing amounts of uPA
to the media of the modified Boyden-chamber assay, the
decrease in SMC migration caused by PAI-1 overexpress-
ing clone EC9 was reversed. These data support the hy-
pothesis that PAI-1 is responsible for the decrease in mi-
gration that we observed.
Zymographic analysis of SMC lysate from cells exposed
to various EC clones revealed significant differences in
MMP activity. Gelatin-based zymography showed dimin-
ished MMP-2 and MMP-9 levels in the SMC exposed to
Fig 6. Representative Western blot for latent MMP-9. Lane 1,
SMC lysate from EC coculture; lane 2, SMC lysate from pCMV/
ER/PAI-1 isolate EC9 coculture; lane 3, purified latent MMP-9.
Fig 7. Effect of PAI-1 transfection on EC proliferation, attach-
ment, and spreading. Top graph shows EC attachment for various
clones after 20 minutes. Attachment assays were done with differ-
ent types of matrix (type I collagen and fibronectin) and on
uncoated glass cover slips. Middle graph shows cell spreading after
40 minutes. Bottom graph shows cell proliferation at various time
points up to 72 hours. Assays run in triplicate, n  6 experiments
with cell passages 4 to 6. P not significant between clones for all
morphologic characteristics.
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PAI-1 overexpressing EC. Mason et al37 have shown that
MMP-9 overexpression increased SMC migration and in-
timal hyperplasia in a rat model. These findings are similar
to ours in which EC overexpression of PAI-1 diminished
SMC MMP activity and decreased SMC migration. The
decrease in MMP-9 activity of the SMC found both on
zymography and Western blot likely inhibits the ability of
these cells to digest their surrounding matrix and migrate.
Our data suggest that EC overexpression of PAI-1 may
favorably affect arterial intimal hyperplasia by downregulat-
ing MMP activity and the subsequent migration of SMC.
A second explanation for the increase in MMP levels
observed in cell lysates of SMCs cocultured opposite con-
trol ECs compared with the PAI-1 overexpressing ECs
could be explained with increased secretion of MMP-2 and
MMP-9 by the ECs themselves. The MMPs secreted by
control ECs possibly could simply cross the semipermeable
membrane and become bound to the SMC. This is unlikely
to have occurred because no differences were observed
between PAI-1 overexpressing and control ECs in the cell
attachment and spreading studies. That a difference would
be found in EC MMP-2 and MMP-9 secretion yet no
difference found in EC spreading or attachment, especially
in view of the multiple types of matrix the studies were
conducted on, is unlikely. Nevertheless, because of the
nature of the coculture system used in these experiments,
this possibility cannot be excluded.
The studies performed to assess the effect of PAI-1
transfection on EC proliferation, attachment, and spread-
ing revealed no differences between overexpressing clones
and control cells. The transfection process did not seem to
alter the attachment, spreading, or proliferation character-
istics of the PAI-1 overexpressing clones. Our attachment
results, as expected, are different from those of Dunn et
al,38 whose studies showed that EC transfected with a
tissue-type plasminogen activator encoding vector had sig-
nificantly diminished attachment abilities compared with
control. This difference is most likely related to the oppos-
ing proteolytic properties of tissue-type plasminogen acti-
vator and PAI-1. However, even though PAI-1 inhibits
proteolysis and one might expect to find enhanced attach-
ment, our transfected cells exhibited normal attachment
properties with the conditions studied.
In summary, our studies revealed that EC overexpres-
sion of PAI-1 inhibits SMC migration and MMP expres-
sion. The mechanism for the decrease in SMC migration is
likely related to PAI-1 inhibition of plasmin generation,
which in turn may diminish SMC MMP-9 activity. EC
overexpression of PAI-1 may ultimately have a favorable
effect on arterial wall repair and remodeling.
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